Answers are grounded in this paper and cite their sources.
Traditional atherosclerosis risk factors cannot elucidate the increased prevalence of cardiovascular events in end stage renal disease (ESRD) patients on hemodialysis. A previous study has indicated a strong association of the PIA1/A2 polymorphism with myocardial infarction, diabetes and renal allograft rejection. In this investigation, we determined the prevalence of the PIA1/A2 polymorphism of platelet glycoprotein (GP) IIb/IIIa in ESRD patients on hemodialysis in the Eastern Province of Saudi Arabia. The PIA1/A2 polymorphism was determined in 42 ESRD patients receiving hemodialysis and in 49 subjects without current or past history of renal disease. Genotypes were determined by a reverse-hybridization assay and were confirmed by restriction fragment length polymorphism procedures. The PIA2 allele frequency among the control sample was 28.6% (2 were homozygous for PIA2, 23 were homozygous for PIA1, and 24 were heterozygous PIA1/A2). The PIA2 allele frequency among the hemodialysis sample was 50% (2 were homozygous for PIA2, 2 were homozygous for PIA1 and 38 were heterozygous for PIA1/A2). The PIA2 allele frequency among the hemodialysis patients was significantly higher than that in the control group [Odds ratios 2.5 (1.35-4.61), p<0.003; Adjusted odds ratios of 2.21 (1.05-4.65), p<0.036 after adjustment for the presence of diabetes; Simultaneously adjusting the odds ratios for the presence of standard risk factors (diabetes and hypertension) gave an adjusted OR of 6.87 (1.54-30.71), p=0.064]. These results suggest that the PIA2 polymorphism may contribute toward the etiology of cardiovascular diseases in ESRD patients. A further study with a larger sample size is needed to confirm above results.
No takes yet. Share an insight, caveat, or question.
Al‐Ali et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: